Cargando…

Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer

Breast cancer (BrC) is the most frequent malignancy and the leading cause of cancer death among women worldwide. Approximately 70% of BrC are classified as luminal-like subtype, expressing the estrogen receptor. One of the most common and effective adjuvant therapies for this BrC subtype is endocrin...

Descripción completa

Detalles Bibliográficos
Autores principales: Amorim, Maria, Lobo, João, Fontes-Sousa, Mário, Estevão-Pereira, Helena, Salta, Sofia, Lopes, Paula, Coimbra, Nuno, Antunes, Luís, Palma de Sousa, Susana, Henrique, Rui, Jerónimo, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749838/
https://www.ncbi.nlm.nih.gov/pubmed/31572437
http://dx.doi.org/10.3389/fgene.2019.00815
_version_ 1783452356820598784
author Amorim, Maria
Lobo, João
Fontes-Sousa, Mário
Estevão-Pereira, Helena
Salta, Sofia
Lopes, Paula
Coimbra, Nuno
Antunes, Luís
Palma de Sousa, Susana
Henrique, Rui
Jerónimo, Carmen
author_facet Amorim, Maria
Lobo, João
Fontes-Sousa, Mário
Estevão-Pereira, Helena
Salta, Sofia
Lopes, Paula
Coimbra, Nuno
Antunes, Luís
Palma de Sousa, Susana
Henrique, Rui
Jerónimo, Carmen
author_sort Amorim, Maria
collection PubMed
description Breast cancer (BrC) is the most frequent malignancy and the leading cause of cancer death among women worldwide. Approximately 70% of BrC are classified as luminal-like subtype, expressing the estrogen receptor. One of the most common and effective adjuvant therapies for this BrC subtype is endocrine therapy. However, its effectiveness is limited, with relapse occurring in up to 40% of patients. Because microRNAs have been associated with several mechanisms underlying endocrine resistance and sensitivity, they may serve as predictive and/or prognostic biomarkers in this setting. Hence, the main goal of this study was to investigate whether miRNAs deregulated in endocrine-resistant BrC may be clinically relevant as prognostic and predictive biomarkers in patients treated with adjuvant endocrine therapy. A global expression assay allowed for the identification of microRNAs differentially expressed between luminal BrC patients with or without recurrence after endocrine adjuvant therapy. Then, six microRNAs were chosen for validation using quantitative reverse transcription polymerase chain reaction in a larger set of tissue samples. Thus, miR-30c-5p, miR-30b-5p, miR-182-5p, and miR-200b-3p were found to be independent predictors of clinical benefit from endocrine therapy. Moreover, miR-182-5p and miR-200b-3p displayed independent prognostic value for disease recurrence in luminal BrC patients after endocrine therapy. Our results indicate that selected miRNAs’ panels may constitute clinically useful ancillary tools for management of luminal BrC patients. Nevertheless, additional validation, ideally in a multicentric setting, is required to confirm our findings.
format Online
Article
Text
id pubmed-6749838
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67498382019-09-30 Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer Amorim, Maria Lobo, João Fontes-Sousa, Mário Estevão-Pereira, Helena Salta, Sofia Lopes, Paula Coimbra, Nuno Antunes, Luís Palma de Sousa, Susana Henrique, Rui Jerónimo, Carmen Front Genet Genetics Breast cancer (BrC) is the most frequent malignancy and the leading cause of cancer death among women worldwide. Approximately 70% of BrC are classified as luminal-like subtype, expressing the estrogen receptor. One of the most common and effective adjuvant therapies for this BrC subtype is endocrine therapy. However, its effectiveness is limited, with relapse occurring in up to 40% of patients. Because microRNAs have been associated with several mechanisms underlying endocrine resistance and sensitivity, they may serve as predictive and/or prognostic biomarkers in this setting. Hence, the main goal of this study was to investigate whether miRNAs deregulated in endocrine-resistant BrC may be clinically relevant as prognostic and predictive biomarkers in patients treated with adjuvant endocrine therapy. A global expression assay allowed for the identification of microRNAs differentially expressed between luminal BrC patients with or without recurrence after endocrine adjuvant therapy. Then, six microRNAs were chosen for validation using quantitative reverse transcription polymerase chain reaction in a larger set of tissue samples. Thus, miR-30c-5p, miR-30b-5p, miR-182-5p, and miR-200b-3p were found to be independent predictors of clinical benefit from endocrine therapy. Moreover, miR-182-5p and miR-200b-3p displayed independent prognostic value for disease recurrence in luminal BrC patients after endocrine therapy. Our results indicate that selected miRNAs’ panels may constitute clinically useful ancillary tools for management of luminal BrC patients. Nevertheless, additional validation, ideally in a multicentric setting, is required to confirm our findings. Frontiers Media S.A. 2019-09-11 /pmc/articles/PMC6749838/ /pubmed/31572437 http://dx.doi.org/10.3389/fgene.2019.00815 Text en Copyright © 2019 Amorim, Lobo, Fontes-Sousa, Estevão-Pereira, Salta, Lopes, Coimbra, Antunes, Palma de Sousa, Henrique and Jerónimo http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Amorim, Maria
Lobo, João
Fontes-Sousa, Mário
Estevão-Pereira, Helena
Salta, Sofia
Lopes, Paula
Coimbra, Nuno
Antunes, Luís
Palma de Sousa, Susana
Henrique, Rui
Jerónimo, Carmen
Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer
title Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer
title_full Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer
title_fullStr Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer
title_full_unstemmed Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer
title_short Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer
title_sort predictive and prognostic value of selected micrornas in luminal breast cancer
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749838/
https://www.ncbi.nlm.nih.gov/pubmed/31572437
http://dx.doi.org/10.3389/fgene.2019.00815
work_keys_str_mv AT amorimmaria predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT lobojoao predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT fontessousamario predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT estevaopereirahelena predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT saltasofia predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT lopespaula predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT coimbranuno predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT antunesluis predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT palmadesousasusana predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT henriquerui predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer
AT jeronimocarmen predictiveandprognosticvalueofselectedmicrornasinluminalbreastcancer